Ruling Request; U.S. International Trade Commission; Limited Exclusion Order; Investigation No. 337-TA-1411; Certain Photodynamic Therapy Systems, Components Thereof, and Pharmaceutical Products Used in Combination with the Same
No Headquarters ruling in this index revokes or modifies this ruling. That is not confirmation that it is still in effect: this index does not hold every Headquarters ruling. Confirm its current status with CBP before relying on it (ruling on CBP CROSS). Text last read from CBP on Nov 21, 2026.
Key passages, quoted from the ruling
- We find that Biofrontera has met its burden to show that the articles at issue do not infringe the asserted claims of the ’512 patent and the ’028 patent, and thus, are not subject to the 1411 LEO, as explained above.
Ruling text
Pursuant to 19 C.F.R. Part 177, the Exclusion Order Enforcement (EOE) Branch, Regulations and Rulings, U.S. Customs and Border Protection (CBP) issues this ruling letter in response to the request, dated June 3, 2026, from Biofrontera Inc., Biofrontera Pharma GmbH, and Biofrontera Bioscience GmbH (collectively, “Respondents” or “Biofrontera”) for an administrative ruling, which included Exhibits 1 to 27 (collectively, “Ruling Request”).
We find that the articles at issue, as described below, are not subject to the limited exclusion order (LEO) issued in U.S. International Trade Commission (ITC or “Commission”) Investigation No. 337-TA- 1411 (“the underlying investigation” or “the 1411 investigation”), pursuant to Section 337 of the Tariff Act of 1930, as amended, 19 U.S.C. § 1337 (“Section 337”).
We note that determinations of the Commission resulting from the underlying investigation or a related proceeding under 19 C.F.R. Part 210 are binding authority on CBP and, in the case of conflict, will by operation of law modify or revoke any contrary CBP ruling or decision pertaining to Section 337 exclusion orders. This ruling letter is the result of a request for an administrative ruling from CBP under 19 C.F.R. Part 177 that the EOE Branch conducted on an inter partes basis.
The proceeding involved the two parties with a direct and demonstrable interest in the question presented by the ruling request: (1) your client, Biofrontera, the ruling requester and respondents in the 1411 investigation; and (2) Sun Pharmaceutical Industries, Inc. (“Sun Pharma” or “Complainant”), the complainant in the 1411 investigation. See 19 C.F.R. § 177.1(c). The parties were asked to clearly identify confidential information with [[red brackets]] in their submissions to CBP.
See, e.g., EOE Branch Email to Parties, dated June 8, 2026; see also 19 C.F.R. §§ 177.2 and 177.8. If there is additional information in this ruling letter not currently bracketed in red [[ ]] that either party believes constitutes confidential information and should be redacted from the published ruling, the parties are directed to contact CBP within ten (10) working days of the date of this ruling letter. See, e.g., 19 C.F.R. § 177.8(a)(3).
Please note that disclosure of information related to administrative rulings under 19 C.F.R. Part 177 is governed by, for example, 6 C.F.R. Part 5, 31 C.F.R. Part 1, 19 C.F.R. Part 103, and 19 C.F.R. § 177.8(a)(3). See, e.g., 19 C.F.R. § 177.10(a). In addition, CBP is guided by the laws relating to confidentiality and disclosure, such as the Freedom of Information Act (FOIA), as amended (5 U.S.C. § 552), the Trade Secrets Act (18 U.S.C. § 1905), and the Privacy Act of 1974, as amended (5 U.S.C. § 552a).
A request for confidential treatment of information submitted in connection with a ruling requested under 19 C.F.R. Part 177 faces a strong presumption in favor of disclosure. See, e.g., 19 C.F.R. § 177.8(a)(3).
The text above is an excerpt. The official ruling, with its letterhead, signature and any attachments, is on CBP CROSS (H361286).